![2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-019-05039-w/MediaObjects/125_2019_5039_Fig1_HTML.png)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
![Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes ca. 2019 #Nephpearls https://t.co/JfHQk8LVyB" / X Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes ca. 2019 #Nephpearls https://t.co/JfHQk8LVyB" / X](https://pbs.twimg.com/media/EbIha2bWkAAlUI0.jpg:large)
Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes ca. 2019 #Nephpearls https://t.co/JfHQk8LVyB" / X
American Diabetes Association - Professional Publications - A new ADA-EASD Consensus Report calls for a paradigm shift in management to a patient-centered approach with shared decision making. It provides a comprehensive review
![From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes | Cardiovascular Diabetology | Full Text From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-021-01281-y/MediaObjects/12933_2021_1281_Fig3_HTML.png)
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes | Cardiovascular Diabetology | Full Text
![2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-019-05039-w/MediaObjects/125_2019_5039_Fig2_HTML.png)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
![JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes](https://www.mdpi.com/jcm/jcm-09-00912/article_deploy/html/images/jcm-09-00912-g001-550.jpg)
JCM | Free Full-Text | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
![Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/asset/b2c0fa87-783e-431b-9875-88b62f1d30c9/gr1.jpg)
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis - The Lancet Diabetes & Endocrinology
![Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X](https://pbs.twimg.com/media/DrrCSHUXgAIxaCB.jpg:large)
Edgar V. Lerma 🇵🇭 on X: "Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt" / X
![Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis - The Lancet Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis - The Lancet](https://www.thelancet.com/cms/asset/7825dcd3-a4e2-4c88-a5af-c684cfec3277/gr1.jpg)